Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease
Caviglia, G.P.; Nicolosi, A.; Abate, M.L.; Carucci, P.; Rosso, C.; Rolle, E.; Armandi, A.; Aneli, S.; Olivero, A.; Risso, A.; Ribaldone, D.G.; Fermer, C.; Saracco, G.M.; Gaia, S.; Bugianesi, E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Curr. Oncol. 2022, 29, 5457-5465. https://doi.org/10.3390/curroncol29080431
Caviglia GP, Nicolosi A, Abate ML, Carucci P, Rosso C, Rolle E, Armandi A, Aneli S, Olivero A, Risso A, Ribaldone DG, Fermer C, Saracco GM, Gaia S, Bugianesi E. Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease. Current Oncology. 2022; 29(8):5457-5465. https://doi.org/10.3390/curroncol29080431
Chicago/Turabian StyleCaviglia, Gian Paolo, Aurora Nicolosi, Maria Lorena Abate, Patrizia Carucci, Chiara Rosso, Emanuela Rolle, Angelo Armandi, Serena Aneli, Antonella Olivero, Alessandra Risso, Davide Giuseppe Ribaldone, Christian Fermer, Giorgio Maria Saracco, Silvia Gaia, and Elisabetta Bugianesi. 2022. "Liver Cancer-Specific Isoform of Serine Protease Inhibitor Kazal for the Detection of Hepatocellular Carcinoma: Results from a Pilot Study in Patients with Dysmetabolic Liver Disease" Current Oncology 29, no. 8: 5457-5465. https://doi.org/10.3390/curroncol29080431